Harmony Biosciences & Newrology: A Fresh Approach
Harmony Biosciences is a commercial-stage pharmaceutical company founded in 2017 and focused on developing and commercializing innovative therapies for people living with rare neurological diseases. The company received FDA approval for its first product in 2019, went public on NASDAQ in 2020, and has since expanded into rare epilepsy through the acquisitions of Zynerba Pharmaceuticals (2023) and Epygenix Therapeutics (2024). Its Newrology platform integrates patient, family, and scientific perspectives to advance unmet needs in sleep/wake disorders and rare epilepsy.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2020
Jan 2018
Oct 2017
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Denali Therapeutics is a biotechnology company focused on discovering and developing treatments f...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Biopharmaceutical company developing sustained-release hydrogel therapies targeting retinal disea...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
